In AVF needle manufacturing, the rigor of quality control directly impacts patient safety. Manufacturers establish a full-process quality management system compliant with ISO 13485 and implement six critical inspection gates covering incoming material verification, in-process surveillance and finished-product release, to achieve zero-defect conformance for every single needle.

Gate 1: Incoming Raw Material Inspection

Each stainless steel batch undergoes spectroscopic analysis to verify chemical composition, ensuring chromium, nickel and molybdenum contents comply with ASTM A269 specifications. Intergranular corrosion testing per the copper sulfate–sulfuric acid method is performed to prevent compromised corrosion resistance induced by carbide precipitation. Manners Technology mandates suppliers to provide Level 3.1 Material Test Certificates containing traceable details such as melt batch numbers and heat treatment parameters, locking in raw material quality at the source.

Gate 2: In-Process Operation Inspection

During grinding, operators conduct hourly sampling checks on tip angle (tolerance ±0.5°) and surface roughness (Ra ≤0.2 μm), examining cutting edge integrity at 50× magnification via optical profile projectors. Post laser cutting, a 3D confocal microscope measures groove width (±0.01 mm) and depth (±0.005 mm) to guarantee flow channel compliance with hydrodynamic design criteria. Statistical Process Control (SPC) charts are deployed at key production steps with a required Process Capability Index (Cpk ≥1.33); production halts immediately for corrective adjustment upon any out-of-spec deviation.

Gate 3: Cleanliness and Microbiological Control

Electropolished needles are subjected to surface particulate testing by laser light scattering: no more than 100 particles ≥0.5 μm shall be present per needle. Endotoxin testing via the Limulus Amebocyte Lysate (LAL) method limits endotoxin content to ≤0.5 EU/mL. Prior to packaging, sterility testing is conducted using the membrane filtration technique; batches are cleared for release only after 14 days of incubation with no microbial growth detected.

Gate 4: Functional Simulation Testing

Manufacturers construct an extracorporeal circulation simulation platform to assess hemodynamic performance using fresh bovine blood or simulated blood with 35% hematocrit, against the following acceptance criteria:

Blood flow ≥300 mL/min for 17G needles;

Trans-needle pressure drop ≤15 mmHg;

No thrombosis or blockage after four consecutive hours of continuous circulation.

Manners Technology additionally carries out in-vivo animal trials on porcine femoral arteriovenous fistula models, targeting ≥98% puncture success rate and ≤1% vascular wall perforation rate to quantify vascular trauma.

Gate 5: Packaging and Label Verification

Packaging integrity is validated via dye penetration testing (zero dye ingress permitted) and vacuum decay testing (leakage rate ≤0.01 mL/min). Label durability is confirmed after repeated alcohol wiping and high-temperature sterilization, with all markings remaining legible. Each Unique Device Identification (UDI) code is scanned against the GS1 database to verify data consistency.

Gate 6: Post-Market Surveillance

Manufacturers maintain an adverse event monitoring system to collect clinical complaints including tip fracture, blood leakage and procedure-related infection. Investigations are initiated within 24 hours of reported incidents, with corrective resolutions issued within 48 hours. Annual management reviews update quality specifications; for instance, the acceptable puncture force threshold for tip sharpness was tightened from 0.8 N down to 0.6 N following updated clinical guidelines.

Conclusion

AVF needle quality control constitutes a full-lifecycle systematic program whereby manufacturers translate ISO 13485 requirements into actionable standard operating procedures. Only rigorous screening across the six inspection gates enables delivery of safe, dependable vascular access devices for hemodialysis patients.